FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Childhood Myelodysplastic Syndromes
Childhood Nasal Type Extranodal NK/T-cell Lymphoma
Chronic Myelomonocytic Leukemia
Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma

Interventions: Drug: fludarabine phosphate
Radiation: total-body irradiation
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Drug: cyclosporine
Drug: mycophenolate mofetil
Other: laboratory biomarker analysis

First Posted Date: 2004-03-09

Last Posted Date: 2020-01-18

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 37

Registration Number: NCT00078858

Locations: 🇺🇸
Stanford University Hospitals and Clinics, Stanford, California, United States
🇺🇸
Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States
🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States

and more 7 locations

Laser Therapy in Preventing Oral Mucositis in Patients Undergoing Bone Marrow Transplantation

Phase 2

Completed

Conditions: Oral Complications

First Posted Date: 2004-02-27

Last Posted Date: 2010-06-17

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00024037

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

First Posted Date: 2004-02-16

Last Posted Date: 2010-04-02

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00027924

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors

Phase 2

Completed

Conditions: Breast Cancer
Gestational Trophoblastic Tumor
Kidney Cancer
Lymphoma
Neuroblastoma
Ovarian Cancer
Sarcoma
Testicular Germ Cell Tumor

First Posted Date: 2004-02-12

Last Posted Date: 2010-04-02

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00004157

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Phase 3

Completed

Conditions: Acute Lymphoblastic Leukemia in Remission
Refractory Hodgkin Lymphoma
Waldenstrom Macroglobulinemia
Acute Myeloid Leukemia in Remission
Aggressive Non-Hodgkin Lymphoma
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Hematopoietic and Lymphoid Cell Neoplasm
Diffuse Large B-Cell Lymphoma
Indolent Non-Hodgkin Lymphoma
Mantle Cell Lymphoma

Interventions: Procedure: Total-Body Irradiation
Drug: Fludarabine Phosphate
Drug: Mycophenolate Mofetil
Drug: Cyclosporine
Procedure: Peripheral Blood Stem Cell Transplantation

First Posted Date: 2004-01-12

Last Posted Date: 2017-05-15

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 87

Registration Number: NCT00075478

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States
🇩🇪
Medizinische Univ Klinik Koln, Koln, Germany

and more 7 locations

Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma

Phase 1

Completed

Conditions: Neuroblastoma

First Posted Date: 2003-12-31

Last Posted Date: 2010-09-21

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00006480

Locations: 🇺🇸
Cancer Center and Beckman Research Institute, City of Hope, Duarte, California, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Previously Treated Myelodysplastic Syndromes
Refractory Anemia With Excess Blasts
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Recurrent Adult Acute Myeloid Leukemia
Secondary Myelodysplastic Syndromes
Untreated Adult Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Chronic Myelomonocytic Leukemia

Interventions: Radiation: iodine I 131 monoclonal antibody BC8
Radiation: total-body irradiation
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Drug: fludarabine phosphate
Drug: cyclosporine
Drug: mycophenolate mofetil
Other: laboratory biomarker analysis

First Posted Date: 2003-12-12

Last Posted Date: 2019-11-13

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 79

Registration Number: NCT00008177

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Nodal Marginal Zone B-cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Marginal Zone Lymphoma
Waldenström Macroglobulinemia
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Lymphoblastic Lymphoma

Interventions: Drug: cyclophosphamide
Drug: etoposide
Radiation: iodine I 131 tositumomab
Procedure: quality-of-life assessment
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-12-11

Last Posted Date: 2017-08-18

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 111

Registration Number: NCT00073918

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-12-11

Last Posted Date: 2015-02-05

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 25

Registration Number: NCT00073931

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis

Phase 2

Completed

Conditions: Chronic Myeloproliferative Disorders

First Posted Date: 2003-11-11

Last Posted Date: 2010-06-17

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00006367

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
University of Illinois College of Medicine, Chicago, Illinois, United States

and more 6 locations

Home Terms & Conditions Privacy Policy